NZ's PHARMAC consults on Humira, Enbrel and Neurontin funding

14 July 2015

New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on a proposal relating to the funding of the TNF-inhibitor medicines adalimumab (Humira), from AbbVie (NYSE: ABBV), and etanercept (Enbrel), from Pfizer (NYSE: PFE) both used to treat people with various autoimmune and immune-mediated conditions, and gabapentin (Neurontin), also from Pfizer, used to treat epilepsy and neuropathic pain.

The effect of the proposal would be to make the funding of the TNF-inhibitor treatments and Neurontin more cost-effective and to create savings of more than A$20 million ($14.8 million) over five years that would enable PHARMAC to deliver greater health outcomes from available pharmaceutical funding.

In summary the proposal is to:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK